Carnegie acted as exclusive defence adviser to Exiqon A/S and its owners in the public tender offer from QIAGEN N.V. Exiqon is a market leading niche player within RNA analysis. It develops, manufactures and markets reagents and kits to test the actual contents on a molecular level of biological samples. The reagents and kits are used in biological research and development of novel medicines and molecular diagnostic tests. June 2016.
Healthcare
Cash offer for Exiqon A/S (DK) by QIAGEN N.V. (NL) — DKK 736 million
June 2016